National Surveys: Opportunities for Evaluation of ADFs

Jana McAninch, MD, MPH, MS
Medical Officer/Epidemiologist
Office of Surveillance and Epidemiology
Center for Drug Evaluation and Research
U.S. Food and Drug Administration
July 11, 2017
Outline

• Why focus on national surveys?
• Building on established national surveys
• Emerging survey methodologies
• Ideal elements in national surveys
• Discussion questions
Why focus on national surveys?

• Some outcomes may be best captured in self-reported data

• Active surveillance
  – Selection not dependent on outcome, treatment availability, etc.
  – Can use probability sampling methods
    • Drug abuse patterns vary geographically—cannot generalize smaller areas to U.S.
    • Can make valid comparisons between products
    • Can reliably trend over time (except when major survey redesign)—useful for pre-post studies
Building on Established National Surveys
National Survey on Drug Use and Health (NSDUH)

- Ongoing nationally representative household survey of the civilian, noninstitutionalized U.S. population aged ≥12 years
- $N \sim 70,000$ interviews per year
- National estimates on drug-taking behaviors, including nonmedical use of prescription pain relievers.
- Major survey redesign in 2015
  - Trend break
  - New data
    - Past-year use and misuse of specific opioid molecules (e.g., hydrocodone, fentanyl)
    - Information on reasons for misuse
    - Still limited data on specific products, formulations, routes
## NSDUH 2015: Example Table

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>ANY PRESCRIPTION PAIN RELIEVER¹</td>
<td>--</td>
<td>36.4</td>
<td>nc</td>
<td>4.7</td>
<td>--</td>
<td>12.8</td>
</tr>
<tr>
<td>Hydrocodone Products</td>
<td>--</td>
<td>21.8</td>
<td>--</td>
<td>2.7</td>
<td>--</td>
<td>12.3</td>
</tr>
<tr>
<td>Zohydro® ER</td>
<td>--</td>
<td>0.1</td>
<td>--</td>
<td>0.0</td>
<td>--</td>
<td>*</td>
</tr>
<tr>
<td>Oxycodone Products</td>
<td>--</td>
<td>10.4</td>
<td>--</td>
<td>1.6</td>
<td>--</td>
<td>15.3</td>
</tr>
<tr>
<td>OxyContin®</td>
<td>--</td>
<td>3.4</td>
<td>nc</td>
<td>0.7</td>
<td>--</td>
<td>19.3</td>
</tr>
<tr>
<td>Tramadol Products</td>
<td>--</td>
<td>6.9</td>
<td>--</td>
<td>0.7</td>
<td>--</td>
<td>9.7</td>
</tr>
<tr>
<td>Morphine Products</td>
<td>--</td>
<td>2.7</td>
<td>--</td>
<td>0.3</td>
<td>--</td>
<td>9.7</td>
</tr>
<tr>
<td>Fentanyl Products</td>
<td>--</td>
<td>0.7</td>
<td>--</td>
<td>0.1</td>
<td>--</td>
<td>15.0</td>
</tr>
<tr>
<td>Buprenorphine Products</td>
<td>--</td>
<td>0.9</td>
<td>--</td>
<td>0.3</td>
<td>--</td>
<td>29.3</td>
</tr>
<tr>
<td>Oxymorphone Products</td>
<td>--</td>
<td>0.5</td>
<td>--</td>
<td>0.1</td>
<td>--</td>
<td>28.9</td>
</tr>
<tr>
<td>Demerol®</td>
<td>--</td>
<td>0.5</td>
<td>--</td>
<td>0.0</td>
<td>--</td>
<td>7.4</td>
</tr>
<tr>
<td>Hydromorphone Products</td>
<td>--</td>
<td>0.9</td>
<td>--</td>
<td>0.1</td>
<td>--</td>
<td>10.5</td>
</tr>
<tr>
<td>Methadone</td>
<td>--</td>
<td>0.6</td>
<td>--</td>
<td>0.2</td>
<td>--</td>
<td>32.0</td>
</tr>
<tr>
<td>Any Other Prescription Pain Reliever²</td>
<td>--</td>
<td>8.9</td>
<td>--</td>
<td>0.3</td>
<td>--</td>
<td>3.8</td>
</tr>
</tbody>
</table>

¹ = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

**NOTE:** Any Use of prescription drugs is defined as (a) the use of one's own prescription medication as directed by a doctor or (b) misuse of prescription drugs. Misuse of prescription drugs is defined as use in any way not directed by a doctor, including use without a prescription of one's own medication, use in greater amounts, more often, or longer than told to take a drug, or use in any other way not directed by a doctor. Prescription drugs do not include over-the-counter drugs.

1 Includes hydrocodone products (Vicodin®, Lortab®, Norco®, Zohydro® ER, generic hydrocodone, or other similar products); oxycodone products (OxyContin®, Percocet®, Percodan®, Roxicet®, Roxicodone®, generic oxycodone, or other similar products); tramadol products (Ultram®, Ultram® ER, Ultracet®, generic tramadol, generic extended-release tramadol, or other similar products); codeine products (Tylenol® with codeine 3 or 4, generic codeine pills, or other similar products); morphine products (Avinza®, Kadian®, MS Contin®, generic morphine, generic extended-release morphine, or other similar products); fentanyl products (Actiq®, Duragesic®, Fentanyl®, generic fentanyl, or other similar products); buprenorphine products (Suboxone®, generic buprenorphine, or other similar products); oxymorphone products (Opana®, Opana® ER, generic oxymorphone, generic extended-release oxymorphone, or other similar products); meperidine products (Demerol® or other similar products); hydromorphone products (Dilaudid® or generic hydromorphone, Exalgo® or generic extended-release hydromorphone, or other similar products); methadone products (methadone or other similar products); or any other prescription pain reliever. Over-the-counter drugs are not included.

2 Includes use or misuse of pain relievers containing other active ingredients. Reports of misuse of "any other prescription pain reliever" that correspond only to the specific pain reliever categories shown in the table are excluded from estimates for Any Other Prescription Pain Reliever and are included instead in the relevant pain reliever category.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2014 and 2015.
NSDUH—Useful in Evaluation of ADF Opioids?

• Has been used to assess changes in OxyContin nonmedical use after reformulation\(^1\)

• Suggestions for future NSDUH redesign?
  ➢ New/revised questions, modules?
  ➢ Adequate sample size to get reliable estimates for products with low market share?
  ➢ Must be feasible to add to lengthy interview

# Other National Health Surveys

## What can we learn from these other surveillance systems?

<table>
<thead>
<tr>
<th>Survey</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monitoring the Future</td>
<td>School-based survey on adolescent drug abuse</td>
</tr>
<tr>
<td></td>
<td>Limited product-specific data</td>
</tr>
<tr>
<td></td>
<td>Longitudinal follow-up component</td>
</tr>
<tr>
<td>National Health and Nutrition Examination Survey</td>
<td>Interviews, physical exam, labs</td>
</tr>
<tr>
<td></td>
<td>Longitudinal follow-up component</td>
</tr>
<tr>
<td>National Health Interview Survey</td>
<td>General health survey</td>
</tr>
<tr>
<td></td>
<td>Methods similar to NSDUH</td>
</tr>
<tr>
<td>Behavioral Risk Factor Surveillance System</td>
<td>Telephone survey</td>
</tr>
<tr>
<td></td>
<td>&gt;400,000 adults per year</td>
</tr>
<tr>
<td></td>
<td>Core and optional modules/questions</td>
</tr>
<tr>
<td>Youth Risk Behavior Surveillance System</td>
<td>School-based survey -- health risk behaviors</td>
</tr>
<tr>
<td></td>
<td>National, state and district level data</td>
</tr>
<tr>
<td>Pregnancy Risk Assessment Monitoring System</td>
<td>Surveys women with recent live birth</td>
</tr>
<tr>
<td></td>
<td>Oversamples some high-risk groups</td>
</tr>
<tr>
<td></td>
<td>Longitudinal follow-up component</td>
</tr>
</tbody>
</table>
Building on Established National Surveys

• Challenges
  ➢ Burdensome to include detailed data on specific marketed products—surveys already lengthy
  ➢ Cumbersome redesign process, not easily adaptable
  ➢ May not capture highest risk individuals
  ➢ Likely low precision for some products, routes
  ➢ Data lag
Emerging Survey Methodologies: Internet-Based Surveys
Emerging Survey Methodologies: “Opt-in” Internet Panels

• Population
  ➢ Survey administration company invites individuals to subscribe to online survey panel
  ➢ Member of this “opt-in” panel volunteer for various surveys

• Sample-matching and weighting techniques can be used to get sample demographic distribution similar to target population (e.g., US adults)

• Surveys can be tailored to examine specific products and questions
“Opt-in” Internet Panels: Examples

• **Inflexxion® Internet Surveys**
  - Cassidy, 2015: Internet-based study on nonmedical use of prescription stimulants\(^1\)
  - Used independent survey research company YouGov®

• **RADARS® NMURx**
  - U.S. launch in 3Q 2016
  - Uses several panel recruiting partners/methods
  - Lifetime, past-year, past 90/30/7-day nonmedical use
  - Product/formulation and route
  - Reasons for nonmedical use

Internet Surveys with Enriched Samples

• Recruit participants from online drug abuse discussion forums (e.g., Bluelight.org\textsuperscript{1})
• Therefore, samples enriched with people abusing drugs
• 2014, 2015 Inflexxion hydrocodone surveys
  – Conducted surveys of visitors to Bluelight.org evaluating patterns of hydrocodone nonmedical use\textsuperscript{2}

1. www.bluelight.org
Internet Surveys—Challenges and Questions

• What is underlying population for Opt-in panels? For drug abuse discussion forum surveys?
• What kinds of selection forces might exist? Might it change over time?
• How valid are inferences to general population, other underlying population?
• Data quality
Designing the Ideal National Survey—Key Elements

• Product- and route-specific
• Rapidly modifiable in response to market changes
• Rigorous efforts to minimize misclassification—especially differential product misclassification
  ➢ Question format: “yes/no/not sure” vs. “select all that apply”?
  ➢ Pill photos?
  ➢ Randomize order of drug groups/products?
Designing the Ideal National Survey—Key Elements

• Probability sampling methods, enabling estimation in different subgroups:
  ➢ Geographic regions
  ➢ Demographic groups
  ➢ Severity of substance use disorder

• Oversampling of high-risk subgroups, regions?

• Opportunity for longitudinal follow-up??

Prospective data collection: even ideal survey can’t collect historical data very well
Discussion Questions
Questions for Discussion

1. Discuss the feasibility, advantages, and disadvantages of modifying established national surveys to collect data for ADF evaluation
Questions for Discussion

2. Discuss the advantages and disadvantages of internet-based surveys, both opt-in general population panels and enriched samples, for evaluating ADFs. In particular, what are the potential selection forces operating, and how might these affect the inferences that we can make?
Questions for Discussion

3. Discuss design strategies for minimizing misclassification, particularly differential product misclassification, in surveys being used to evaluate ADFs.
Questions for Discussion

4. Discuss whether a novel survey is needed to collect data for evaluation of ADFs? If so, discuss the feasibility of and ideal approach to developing such a survey.
Questions for Discussion

5. Discuss the feasibility of using internet or other types of survey panels longitudinally (following individual participants over time) to evaluate ADFs.